



Imugene discontinues ibuprofen development

Melbourne, 18 September 2013: Australian drug development and pharmaceutical company Imugene (ASX:IMU) today announced that it has discontinued development of its fast melt ibuprofen tablets.

Imugene has been developing an ibuprofen tablet that melts in the mouth, which attempted to address issues of unpleasant taste, mouth feel and swallowing difficulties associated with the non-steroidal anti-inflammatory drug ibuprofen.

Dr Nick Ede, Executive Director of Imugene said, "With orally dispersible melt-in-the-mouth drugs, it's all about taste and mouth feel. Unfortunately testing of our ibuprofen meltlet has been disappointing, and hence this project has been discontinued".

"Imugene is now a pharmaceutical business with a drug delivery platform at the centre of its assets. Our Linguet™ technology continues to show promise in drugs and nutraceuticals that benefit from direct delivery into the blood stream via the buccal and sub-lingual mucosa", added Dr Ede.

For more information please visit www.imugene.com

Ends

Investor contact:

Dr Nick Ede, Imugene – +61 400 642 254 / [nede\[at\]imugene.com](mailto:nede[at]imugene.com)

About Imugene

Imugene Limited (ASX:IMU) is commercialising drug delivery applications based on its novel buccal (drugs administered via the cheek) Linguet™ technology. Linguet™ is a patient friendly and cost effective system used to deliver established pharmaceutical and nutraceutical products.

For personal use only